02 Jun 2015
Altitude illnessAltitude illness is the term used to describe a number of conditions that may occur shortly after individuals ascend rapidly to high altitude
Travel to high altitude is becoming increasingly accessible and popular.
Most trips to altitude can be enjoyed safely if sensible precautions are taken.
Altitude illness describes a number of conditions that may occur in individuals ascending rapidly to high altitude, usually above 2,500m.
Severe altitude illness is a life-threatening condition and requires urgent attention.
When travelling to altitude adequate travel insurance is essential.
The key to preventing high altitude illness is gradual ascent with regular rests days.
People with pre-existing medical conditions should consult with their healthcare provider prior to travel.
In recent years travel to high altitude has become increasingly popular and accessible . High altitude is defined as an elevation above 1,500m and can be subdivided into the following categories: high altitude 1,500m–3,500m, very high altitude 3,500-5,500m and extreme altitude >5,500m . Altitude illness rarely occurs at altitudes lower than 2,500m.
Altitude illness is the term used to describe a number of conditions that may occur shortly after individuals ascend rapidly to high altitude. Altitude illnesses include acute mountain sickness (AMS), high altitude cerebral oedema (HACE) and high altitude pulmonary oedema (HAPE).
With increasing altitude the percentage of inspired oxygen remains constant at 21 percent; however the air pressure (barometric pressure) decreases. This results in a reduced number of oxygen molecules taken in with each breath and ultimately to reduced oxygen delivery to the body’s tissues. If an individual ascends gradually to high altitude the human body is usually able to adjust to these reduced oxygen levels. This adjustment process is known as acclimatisation. If ascent is too swift, then acclimatisation may not occur rapidly enough and altitude illness may ensue .
High altitude regions of the world include the Himalayas (Asia), Andes (South America), Rocky Mountains (North America), Alps (Europe) and the Caucasus (Europe/Asia).
Popular high altitude destinations for UK travellers include: Everest Base Camp and the Annapurna Circuit in Nepal (5,380m); Mount Kilimanjaro in Tanzania (5,895m); the Inca Trail in Peru (max ~4,200m); Aconcagua in Argentina (6,960m); Mount Kinabalu in Malaysian Borneo (4,095m) and Mount Fuji in Japan (3,776m).
Cities located at high altitude include: Lhasa, Tibet (3,658m); La Paz, Bolivia (3,630m); Cuzco, Peru (3,399m); Quito, Ecuador (2,819m); Bogotá, Colombia (2,644m); Addis Ababa (2,408m) and Johannesburg, South Africa (1,750m). Country Information pages highlight if there is a point of elevation over 2,500m in a country.
Risk for travellers
Epidemiological studies of altitude illness report marked variation in prevalence, mainly as a result of methodological differences. Approximately 9-25 percent of unacclimatised individuals ascending to 2,000-3,000m develop AMS compared to 35-50 percent of those ascending to 3,500-4,500m [4-6]. HACE and HAPE are much less common than AMS. Both are extremely rare below 2,800m and seem to occur at an incidence of around 1-2 percent at altitudes between 4-5,000m .
Risk of developing altitude illness is determined by both factors relating to the trip and factors relating to the individual. Risk factors relating to the trip include: the rate of ascent, absolute change in altitude and sleeping altitude . These are important to consider when planning a trip to altitude. Ideally expeditions or treks should comply with Wilderness Medicine Society suggested maximum ascent rates  (see preventing altitude illness). Treks with a rapid ascent rate (e.g. the ascent of Mount Kilimanjaro in less than 7 days) are of concern [9, 10]. Risk factors relating to the individual include: previous history of altitude illness, normal residence below 900m, exertion on arrival to altitude and certain pre-existing cardiovascular conditions . Physical fitness does not appear to protect against altitude illness . Despite knowledge of these risk factors, accurately determining an individual’s susceptibility to altitude illness is not possible. Previous performance at altitude is probably the best predictor.
The Wilderness Medicine Society has combined knowledge of individual and trip-related risk factors to categorise the risk of AMS. These risk groups refer to unacclimatised individuals. The altitudes correspond to sleeping altitude and they assume ascent will start from elevations < 1200m .
Table 1: Wilderness Medicine Society Risk categories for Acute Mountain Sickness
Signs and symptoms
AMS and HACE are the neurological forms of altitude illness and are likely to represent two points on a spectrum of the same disease with HACE being the more severe form. AMS typically occurs 6-10 hours after ascent to >2,500m (but may rarely occur at altitudes between 1500-2500m) . The Lake Louise Consensus Group defined AMS as the onset of headache in an unacclimatised individual who has recently arrived at altitude accompanied by one or more of the following: gastrointestinal symptoms (anorexia, nausea, vomiting), dizziness, sleep disturbance, fatigue or weakness . The Lake Louise criteria are a useful guide but are mainly used as a research tool and in general any new symptoms occurring after ascending to altitude should be regarded as altitude illness until proven otherwise. AMS is usually benign and self-limiting and if further ascent is delayed it tends to resolve in 1-3 days .
HACE is caused by swelling of the brain (cerebral oedema) and is characterized by the onset of confusion, altered consciousness and or incoordination (ataxia). HACE is commonly preceded by AMS . HAPE is the respiratory form of altitude illness. Initial symptoms include breathlessness on exertion, and a dry cough. These may progress to breathlessness at rest, breathlessness when lying flat, a wet cough, blood stained sputum, wheeze and chest tightness . HAPE may occur in the absence of AMS. HAPE and HACE tend to occur at least 2 days after ascent to altitude greater than 3-4,000m and rarely occur at altitudes lower than 2,800m . They are uncommon but severe forms of altitude illness and frequently occur together. Without intervention they may rapidly progress to death .
Headache and sleep disturbance at high altitude are very common . Despite forming part of the diagnostic criteria for AMS they often occur independently. Periodic breathing at altitude describes the cycle of rapid breathing (hyperventilation) alternating with episodes of decreased breathing (hypoventilation) and pauses in breathing (apnoea) . Individuals often wake during apnoeic episodes and although alarming for those affected or their companions it is usually harmless.
Diagnosis and treatment
AMS, HACE and HAPE are all diagnosed based on clinical findings . The severity of AMS is determined subjectively by the intensity of the symptoms reported by the individual . Specific tests may be helpful to exclude other causes of an individual’s symptoms. It is important to remember that many high altitude settings are based in remote locations away from medical care. Treatment guidelines are based on the Wilderness Medicine Society guidelines . Severe AMS, HACE and HAPE require urgent medical attention with oxygen therapy and descent to a lower altitude where possible. Medical treatments for AMS and HACE include acetazolamide and dexamethasone and for HAPE include nifedipine.
Preventing altitude illness
Serious altitude illness or dying as a result of altitude related illness is avoidable in most cases . The following prevention guidelines are based largely on the Wilderness Medicine Society guidelines .
- Awareness of the symptoms of altitude illness is crucial. Remember altitude illness can and does kill people each year. Symptoms at altitude are caused by altitude illness until proven otherwise.
- Never ascend to sleep at a higher altitude in the presence of symptoms of altitude illness.
- Always attempt to descend if symptoms of altitude illness worsen at a given altitude or if symptoms are severe.
- Never leave an individual with altitude illness alone.
- Always trek with an experienced guide.
- Travel insurance should adequately cover the itinerary and activities. The planned maximum altitude should be disclosed and emergency evacuation by helicopter included within the policy.
- Where possible avoid travel from altitudes less than 1,200m to altitudes greater than 3,500m in a single day.
- Above 3,000m avoid increasing sleeping elevation by more than 500m a day and ensure a rest day (at the same altitude) every three or four days.
- Preventative medications are not necessary for low risk situations (see Table 1) and individuals should rely on gradual ascent.
- Preventative medications may be considered in addition to gradual ascent in moderate or high-risk situations (see Table 1).
- Preventative medications are not a substitute for gradual ascent.
- Acetezolamide (Diamox®) is the preferred drug (unlicensed). The recommended dose is 125mg twice daily to be commenced one to two days prior to reaching 3,500m and then continued for at least two days after reaching the highest altitude.
- A trial dose of Diamox® for one or two days should be taken prior to travel to check for side effects which include: increased urine production (diuresis), pins and needles (paraesthesia), nausea, vomiting, headache and taste disturbance.
- Diamox® is contraindicated in those with severe allergy to sulfa-based drugs and in pregnant women particularly in the first trimester .
- Dexamethasone is an effective alternative to acetazolamide for prevention of AMS.
- Evidence for the benefit of gingko biloba and coca is either inconclusive or lacking .
Pre-existing health problems
These must be carefully considered in consultation with a health professional prior to ascent for the following reasons: Access to health care and medications is often limited in remote high altitude locations; certain medical problems (e.g. some forms of congenital heart disease) may increase the risk of altitude illness; certain medical problems may limit individual-performance or worsen at high altitude for example chronic obstructive pulmonary disease (COPD) or angina.
There is a lack of data regarding the safety of travel to altitude whilst pregnant. It is prudent to avoid high altitude in the first trimester and advisable that at least one scan has been performed to confirm a healthy intrauterine pregnancy .
After 20 weeks gestation short stays (hours to days) at altitudes up to 2,500m without heavy exercise in women with uncomplicated pregnancies are thought to pose minimal risk . The World Health Organization (WHO) state that travel to sleeping altitudes over 3,000m or to remote areas is not advisable during pregnancy .
Women with complicated pregnancies of any gestation should also avoid travel to high altitude for example those with unexplained bleeding, preeclampsia or risk factors for preeclampsia.
The Summary of Product Characteristics for acetazolamide states that this drug should not be used during pregnancy, particularly during the first trimester .
Making specific recommendations for children ascending to altitude is difficult due to the lack of evidence. Children are not thought to be at higher risk of developing altitude illness compared to adults and travel to altitudes up to 2,500m is considered to be low risk in healthy children [20, 21]. Younger, particularly pre-verbal, children may have difficulty communicating symptoms of altitude illness making diagnosis challenging. Healthy children older than 8 years are likely to be capable of communicating their symptoms effectively and will usually present in a similar way to adults .
First Published : 02 Jun 2015
Last Updated :  15 May 2016
- Imray C, Booth A, Wright A, et al. Acute altitude illnesses. BMJ. 2011; 343: d4943.
- Hackett P R and Roach R R. High altitude medicine In: Wilderness Medicine. 6 ed. St Louis: Elsevier/Mosby; 2011.
- Palmer BF. Physiology and pathophysiology with ascent to altitude. Am J Med Sci. 2010; 340(1): 69-77.
- Honigman B, Theis MK, Koziol-McLain J, et al. Acute mountain sickness in a general tourist population at moderate altitudes. Ann Intern Med. 1993; 118(8): 587-92.
- Maggiorini M, Buhler B, Walter M, et al. Prevalence of acute mountain sickness in the Swiss Alps. BMJ. 1990; 301(6756): 853-5.
- Hackett PH, Rennie D and Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet. 1976; 2(7996): 1149-55.
- Barry PW and Pollard AJ. Altitude illness. Bmj. 2003; 326(7395): 915-9.
- Hackett PH and Roach RC. High-altitude illness. N Engl J Med. 2001; 345(2): 107-14.
- Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. Wilderness Environ Med. 2014; 25(4 Suppl): S4-14.
- Shah NM, Windsor JS, Meijer H, et al. Are UK commercial expeditions complying with wilderness medical society guidelines on ascent rates to altitude? J Travel Med. 2011; 18(3): 214-6.
- Sutton JR, Houston CS and Coates GU. The Lake Louise acute mountain sickness scoring system. In: Hypoxia and Molecular Medicine: Proceedings of the 8th International Hypoxia Symposium Held at Lake Louise. Canada: Queen City Printers; 1993. p. 272–274.
- Hackett PH and Roach RC. High altitude cerebral edema. High Alt Med Biol. 2004; 5(2): 136-46.
- Bartsch P and Swenson ER. Acute high-altitude illnesses. N Engl J Med. 2013; 369(17): 1666-7.
- Wilson MH, Newman S and Imray CH. The cerebral effects of ascent to high altitudes. Lancet Neurol. 2009; 8(2): 175-91.
- Zafren K. Prevention of high altitude illness. Travel Med Infect Dis. 2014; 12(1): 29-39.
- Amdipharm Mercury, Acetazolamide 250mg Tablets Summary of Product Characteristics [Accessed 21st April 2015]
- Jean D and Moore LG. Travel to high altitude during pregnancy: frequently asked questions and recommendations for clinicians. High Alt Med Biol. 2012; 13(2): 73-81.
- Jean D, Leal C, Kriemler S, et al. Medical recommendations for women going to altitude. High Alt Med Biol. 2005; 6(1): 22-31.
- World Health Organization. Health risks and precautions: general considerations. In: International Travel and Health: Situation as on 1 January 2012. World Health Organization; 2010. p. 6.
- Pollard AJ, Niermeyer S, Barry P, et al. Children at high altitude: an international consensus statement by an ad hoc committee of the International Society for Mountain Medicine, March 12, 2001. High Alt Med Biol. 2001; 2(3): 389-403.
- Yaron M and Niermeyer S. Travel to high altitude with young children: an approach for clinicians. High Alt Med Biol. 2008; 9(4): 265-9.